|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Molecular Physiology & Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, United States
* To whom correspondence should be addressed. E-mail: alyssa.hasty{at}vanderbilt.edu.
Obesity is increasing at an alarming rate, and its related disorders are placing a considerable strain on our healthcare system. Although they are not always coincident, obesity is often accompanied by hyperlipidemia. Both obesity and hyperlipidemia are independently associated with atherosclerosis, non-alcoholic fatty liver disease (NAFLD), and insulin resistance (IR). Thus, we sought to determine the relative contributions of obesity and hyperlipidemia to these associated pathologies. Obese agouti (Ay/a) mice and their littermate controls (a/a) were placed on an LDLR-/- background. At four months of age, mice were either maintained on chow diet (CD) or placed on Western diet (WD) for 12 weeks. These genetic and dietary manipulations yielded four experimental groups: 1) Lean- a/a;LDLR-/-CD; 2) genetic-induced obesity (GIO)- Ay/a;LDLR-/-CD; 3) diet-induced obesity (DIO)- a/a;LDLR-/-WD; and 4) genetic- plus diet-induced obesity (GIO/DIO)- Ay/a;LDLR-/-WD. Lipoprotein profiles revealed increased VLDL and LDL particles in WD-fed mice compared to CD-fed controls. The hyperlipidemia present in this mouse model was the result of both increased hepatic triglyceride production and delayed lipoprotein clearance from the plasma. Both WD-fed groups exhibited similar levels of atherosclerotic lesion area, with increased obesity in the GIO/DIO group having no impact on atherogenesis. However, the severe obesity in the GIO/DIO group did aggravate NAFLD and IR. These findings suggest that while obesity and hyperlipidemia exert individual pathological effects, the combination of the two has the potential to exert an additive effect on NAFLD and IR, but not atherosclerosis in this mouse model.
This article has been cited by other articles:
![]() |
X. Qi, J. T. Reed, G. Wang, S. Han, E. W. Englander, and G. H. Greeley Jr. Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R429 - R435. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Lloyd, J. McCormick, J. Helmering, K. W. Kim, M. Wang, P. Fordstrom, S. A. Kaufman, R. A. Lindberg, and M. M. Veniant Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E496 - E505. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Nuotio-Antar, D. L. Hachey, and A. H. Hasty Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1517 - E1528. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |